Keyphrases
Cisplatin
100%
Phase II Study
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Concurrent Chemoradiotherapy
100%
Induction Chemoradiotherapy
100%
Surgical Resection
40%
Oral Fluoropyrimidine
40%
Adverse Reactions
40%
Patient-completed
20%
Complete Response
20%
Partial Response
20%
Radiotherapy
20%
Chemoradiotherapy
20%
Anticancer Effect
20%
Neutropenia
20%
Preoperative Therapy
20%
Non-small Cell Lung Cancer (NSCLC)
20%
S-1 Plus Cisplatin
20%
Preoperative Treatment
20%
Twice Daily
20%
Total Dose
20%
Neoadjuvant Setting
20%
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA)
20%
Resectable Lung Cancer
20%
New Treatment Options
20%
Downstaging
20%
Hilar
20%
Leukocytopenia
20%
Mediastinal Lymph Node Metastasis
20%
Chest Wall Invasion
20%
Induction Treatment
20%
Medicine and Dentistry
Chemoradiotherapy
100%
Cisplatin
100%
Non Small Cell Lung Cancer
100%
Surgery
28%
Adverse Event
28%
Lymph Node Metastasis
14%
Radiation Therapy
14%
Malignant Neoplasm
14%
Neutropenia
14%
Preoperative Treatment
14%
Thoracic Wall
14%
Fluoropyrimidine
14%
Transbronchial Aspiration
14%
Endobronchial Ultrasonography
14%
Leukopenia
14%
Mediastinal Lymph Node
14%
Fluoropyrimidine Derivative
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chemoradiation Therapy
100%
Cisplatin
100%
Non Small Cell Lung Cancer
100%
Adverse Event
28%
Lymph Node Metastasis
14%
Malignant Neoplasm
14%
Neutropenia
14%
Fluoropyrimidine
14%
Leukopenia
14%
Fluoropyrimidine Derivative
14%